TABLE 3.
Overview of recommendations.
| PICO number | PICO question | Recommendation |
|---|---|---|
| PICO 1 | In adult lung transplant recipients, should azithromycin be used to prevent the onset of CLAD? | In adult lung transplant recipients, we suggest using azithromycin to prevent the onset of CLAD Conditional recommendation in favor of the intervention, very low certainty of evidence |
| PICO 2 | In adult lung transplant recipients, should tacrolimus be used over cyclosporine to prevent the onset of CLAD? | In adult lung transplant recipients, we recommend using tacrolimus over cyclosporine in the prevention of CLAD Strong recommendation in favor of the intervention, low certainty of evidence |
| PICO 3 | In adult lung transplant recipients, should mycophenolate mofetil be used over azathioprine to prevent the onset of CLAD? | In adult lung transplant recipients, we suggest using either mycophenolate mofetil or azathioprine to prevent the onset of CLAD Conditional recommendation for either the intervention or the comparison, low certainty of evidence |
| PICO 4 | In adults with (progressive) CLAD, should extracorporeal photopheresis be used? | In adults with (progressive) CLAD, we suggest either using extracorporeal photopheresis or not using it Conditional recommendation for either the intervention or the comparison, very low certainty of evidence |
| PICO 5 | In adults with (progressive) CLAD, should anti-thymocyte globulin be used? | In adults with (progressive) CLAD, we suggest either using anti-thymocyte globulin or not using it Conditional recommendation for either the intervention or the comparison, very low certainty of evidence |
| PICO 6 | In adults with (progressive) CLAD, should alemtuzumab be used? | In adults with (progressive) CLAD, we suggest either using alemtuzumab or not using it Conditional recommendation for either the intervention or the comparison, very low certainty of evidence |
| PICO 7 | In adults with (progressive) CLAD, should antifibrotics be used? | In adults with (progressive) CLAD phenotype BOS, we suggest not using antifibrotic therapy with pirfenidone Conditional recommendation against the intervention, low certainty of evidence In adults with (progressive) CLAD phenotype RAS, we suggest either using antifibrotic therapy with pirfenidone or not using it Conditional recommendation for either the intervention or the comparison, low certainty of evidence |
| PICO 8 | In adults with (progressive) CLAD, should montelukast be used? | In adults with (progressive) CLAD, we suggest either using montelukast or not using it Conditional recommendation for either the intervention or the comparison, low certainty of evidence |
BOS, bronchiolitis obliterans syndrome; CLAD, chronic lung allograft dysfunction; RAS, restrictive allograft syndrome.